» Articles » PMID: 30813391

Jumping on the Bandwagon: A Review on the Versatile Applications of Gold Nanostructures in Prostate Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Mar 1
PMID 30813391
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer (PCa) has remarkably emerged as a prominent disease in the face of the male population. Conventional treatments like prostatectomy or radiation can be curative only if PCa is diagnosed at an early stage. In the field of targeted therapy, a bevy of novel therapeutic approaches have left a landmark in PCa treatment and have proven to extend survival via distinct modes of actions. Nanotherapy has started to take root and has become the hype of the century by virtue of its abundant advantages. Scientists have invested a great deal of interest in the development of nanostructures such as gold nanoparticles (AuNPs), which hold particularly great hope for PCa theranostics. In this article, we present an overview of the studies published after 1998 that involve the use of different functionalized AuNPs to treat and diagnose PCa. Special reference is given to various in vitro and in vivo methods employed to shuttle AuNPs to PCa cells. Major studies show an enhancement of either detection or treatment of PCa when compared to their non-targeted counterparts, especially when AuNPs are tagged with specific ligands, such as antibodies, tea natural extracts, folate, anisamide, receptor inhibitors, and chitosan. Future approaches of treatment are dependent on those worthy multifunctional molecules, and are dictated by their ability to achieve a more versatile cancer therapeutic approach.

Citing Articles

D2B-Functionalized Gold Nanoparticles: Promising Vehicles for Targeted Drug Delivery to Prostate Cancer.

Sarkis M, Minassian G, Mitri N, Rahme K, Fracasso G, El Hage R ACS Appl Bio Mater. 2023; 6(2):819-827.

PMID: 36755401 PMC: 9945086. DOI: 10.1021/acsabm.2c00975.


Surface-functionalised hybrid nanoparticles for targeted treatment of cancer.

Tariq H, Bokhari S IET Nanobiotechnol. 2020; 14(7):537-547.

PMID: 33010128 PMC: 8676046. DOI: 10.1049/iet-nbt.2020.0073.

References
1.
Lu L, Li K, Mao Y, Qu H, Yao B, Zhong W . Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo. Int J Oncol. 2017; 51(4):1089-1103. PMC: 5592865. DOI: 10.3892/ijo.2017.4095. View

2.
Wissing S, Kayser O, Muller R . Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004; 56(9):1257-72. DOI: 10.1016/j.addr.2003.12.002. View

3.
Khoo A, Cho S, Reynoso F, Aliru M, Aziz K, Bodd M . Radiosensitization of Prostate Cancers In Vitro and In Vivo to Erbium-filtered Orthovoltage X-rays Using Actively Targeted Gold Nanoparticles. Sci Rep. 2017; 7(1):18044. PMC: 5741750. DOI: 10.1038/s41598-017-18304-y. View

4.
Vural T, Tugce Yaman Y, Ozturk S, Abaci S, Denkbas E . Electrochemical immunoassay for detection of prostate specific antigen based on peptide nanotube-gold nanoparticle-polyaniline immobilized pencil graphite electrode. J Colloid Interface Sci. 2017; 510:318-326. DOI: 10.1016/j.jcis.2017.09.079. View

5.
van Rij C, Frielink C, Goldenberg D, Sharkey R, Lutje S, McBride W . Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide. Cancer Biother Radiopharm. 2014; 29(8):323-9. PMC: 4186637. DOI: 10.1089/cbr.2014.1660. View